AD trial discontinued - limited CGS impact
Filed with ASX · · 2 pages · English
Earlier from Cogstate
- Cogstate announces European approval for Cognigram
- Business Update & Appendix 4C
- Cogstate Establishes Rare Disease and Pediatric Expertise
- S&P DJ Indices Announces March Quarterly Rebalance
- Appendix 4D & Half Year Financial Report
Later from Cogstate
- Full Year Financial Results Summary
- AGM Presentation
- Change of Director’s Interest Notice
- FY19 Half Year Results and Earnings Guidance
- Issue of Placement Shares
Follow Cogstate into a list and get an email when it puts out news.
Follow Cogstate